VANCOUVER, Aug. 21 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) today
reported financial results for the quarter ended June 30, 2009. Amounts,
unless specified otherwise, are expressed in Canadian dollars and in
accordance with Canadian Generally Accepted Accounting Principles (Canadian
GAAP).
Summary Q2 2009 Results
We incurred a net and comprehensive loss of $556,886 for the three months
ended June 30, 2009 compared to a net and comprehensive loss of $671,290 for
the three months ended June 30 2008, representing a decrease of approximately
$114,404. The decrease in our net and comprehensive loss was principally
caused by a decrease in both research and development expenses and general and
administrative expenses.
Interest income for the three months ended June 30, 2009 was $621,
compared to $4,646 for the three month period ending June 30, 2008, resulting
in a decrease of $4,025. The lower interest income earned in the three month
period ending June 30, 2009, as compared to the same period in 2008 was a
result of smaller cash and short term investments balances held in our
treasury in 2009 combined with lower interest rates.
Research and development expenses were $280,116 for the three months
ended June 30, 2009 compared to $365,276 for the three months ended June 30,
2008, representing a decrease of $85,160, primarily due to a reduction in
personnel salaries and consultants' fees.
For the three months ended June 30, 2009 general and administrative
expenses were $201,940 compared to $243,742 for the three months ending June
30, 2008, representing a decrease of $41,802. This decrease in the three
months ending June 30, 2009 compared to the three months ending June 30, 2008
were attributable to decreases in personnel salaries and professional fees.
Amortization for the three months ended June 30, 2009 was $28,825
compared to amortization of $28,792 for the three months ended June 30, 2008,
an increase of $33. Amortization for the six months ended June 30, 209 was
$57,764 compared to amortization of $57,957 for the six months ended June 30,
2008, an increase of $193.
Foreign exchange loss for the three months ended June 30, 2009 was $8,918
compared to foreign exchange gain of $7,673 for the same period in 2008,
representing a decrease of $16,591. Foreign exchange loss for the six months
ended June 30, 2009 was $27,070 compared to foreign exchange gain of $8,632
for the same period in 2008, representing a decrease of $35,702.
Stock based compensation for the three months ended June 30, 2009 was
$37,708 compared to $45,799 for the three months ended June 30, 2008, a
decrease of $8,091.
